<p>隨着全球市場密切關注經濟指標和中央銀行的決策，亞洲股市正在應對一個複雜的環境，既有機遇也有挑戰。在這種環境中，識別那些交易價格低於其內在價值的股票，對於希望在該地區抓住潛在增長機會的投資者來説，可以是一種戰略性的方法。</p>
<h3>基於現金流的亞洲十大被低估股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>當前價格</strong></td>
<td><strong>公允價值（估算）</strong></td>
<td><strong>折扣（估算）</strong></td>
</tr>
<tr>
<td>西安諾瓦星科技（SZSE:301589）</td>
<td>CN¥154.22</td>
<td>CN¥302.65</td>
<td>49%</td>
</tr>
<tr>
<td>廈門特寶生物（SHSE:688278）</td>
<td>CN¥83.18</td>
<td>CN¥161.78</td>
<td>48.6%</td>
</tr>
<tr>
<td>新龍新材料（SZSE:301565）</td>
<td>CN¥28.14</td>
<td>CN¥55.48</td>
<td>49.3%</td>
</tr>
<tr>
<td>美圖（SEHK:1357）</td>
<td>HK$7.47</td>
<td>HK$14.60</td>
<td>48.8%</td>
</tr>
<tr>
<td>最後一公里有限公司（TSE:9252）</td>
<td>¥3530.00</td>
<td>¥6867.62</td>
<td>48.6%</td>
</tr>
<tr>
<td>JUSUNG ENGINEERING 有限公司（KOSDAQ:A036930）</td>
<td>₩29250.00</td>
<td>₩56972.54</td>
<td>48.7%</td>
</tr>
<tr>
<td>東買控股（SEHK:1797）</td>
<td>HK$20.44</td>
<td>HK$40.26</td>
<td>49.2%</td>
</tr>
<tr>
<td>COVER（TSE:5253）</td>
<td>¥1562.00</td>
<td>¥3094.02</td>
<td>49.5%</td>
</tr>
<tr>
<td>中國如意控股（SEHK:136）</td>
<td>HK$2.41</td>
<td>HK$4.80</td>
<td>49.8%</td>
</tr>
<tr>
<td>北京北摩高科技摩擦材料有限公司（SZSE:002985）</td>
<td>CN¥28.28</td>
<td>CN¥55.83</td>
<td>49.3%</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們基於現金流的 277 只被低估亞洲股票的完整列表。</p>
<p>在這裏，我們突出了一部分我們偏好的股票。</p>
<h2>寧波三星醫療電氣有限公司（SHSE:601567）</h2>
<p><strong>概述：</strong> 寧波三星醫療電氣有限公司在中國及國際市場上製造和銷售電力配電產品，市值為 325.2 億人民幣。</p>
<p><strong>運營：</strong> 寧波三星醫療電氣有限公司通過製造和銷售電力配電產品在國內外產生收入。</p>
<p><strong>公允價值折扣估算：</strong> 26%</p>
<p>寧波三星醫療電氣有限公司的交易價格為 23.14 元，顯著低於其估算的公允價值 31.29 元，表明其可能被低估。儘管近期波動較大，但預計該股票的收益在未來三年將以 28.81% 的年率增長，超過中國市場整體 27.2% 的增長率。然而，其 4.19% 的股息收益率並未得到當前收益或自由現金流的良好覆蓋，這對尋求收入穩定的投資者構成潛在風險。</p>
<ul>
<li>我們的收益增長報告揭示了寧波三星醫療電氣有限公司未來業績顯著增長的潛力。</li>
<li>通過閲讀我們的健康報告，深入瞭解寧波三星醫療電氣有限公司的資產負債表。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2ee373e6-53d5-4c83-90e5-36fd85262791/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2ee373e6-53d5-4c83-90e5-36fd85262791/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>SHSE:601567 截至 2025 年 12 月的折現現金流</p>
<h2>南亞新材料科技有限公司（SHSE:688519）</h2>
<p><strong>概述：</strong> 南亞新材料科技有限公司專注於複合材料的製造、設計、開發和銷售，市值為 159.1 億人民幣。</p>
<p><strong>運營：</strong> 該公司通過其核心活動製造、設計、開發和銷售複合材料來產生收入。</p>
<p><strong>公允價值折扣估算：</strong> 15.7%</p>
<p>南亞新材料科技有限公司的交易價格為 69.5 元，低於其估算的公允價值 82.48 元，表明其可能被低估。該公司報告稱，2025 年前九個月的收入顯著增長至 36.6 億人民幣，淨收入從去年同期的 158.1 百萬人民幣上升。儘管股價波動較大且預計的股本回報率較低，但預計未來三年收益將顯著快於市場平均水平。</p>
<ul>
<li>我們最近的增長報告提供了南亞新材料科技有限公司商業前景的良好預測。</li>
<li>點擊探索我們在南亞新材料科技有限公司資產負債表健康報告中的詳細發現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1a885788-1638-4b9b-a3c1-7d0dc71239fc/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1a885788-1638-4b9b-a3c1-7d0dc71239fc/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>SHSE:688519 截至 2025 年 12 月的折現現金流</p>
<h2>MonotaRO（TSE:3064）</h2>
<p><strong>概述：</strong> MonotaRO 有限公司經營一個面向日本及國際工廠的 MRO 產品在線商店，市值為 1.11 萬億日元。</p>
<p><strong>運營：</strong> 該公司的收入主要來自其為工廠提供的間接材料銷售業務，收入為 3180.1 億日元。</p>
<p><strong>公允價值折扣估算：</strong> 16.6%</p>
<p>MonotaRO 的交易價格為 2230 日元，低於其估算的公允價值 2674.47 日元。最近的銷售數據顯示，2025 年 10 月的銷售額達到 294.2 億日元，而去年同期為 253.5 億日元。預計收益將以 13.5% 的年率增長，超過日本市場的平均 8.3%，同時收入增長也預計將超過市場水平。然而，該股票近期經歷了較高的波動，並且基於現金流的公允價值僅略低。</p>
<ul>
<li>我們精心準備的 MonotaRO 增長報告暗示其未來財務前景可能強於近期業績。</li>
<li>點擊這裏訪問我們的完整資產負債表健康報告，以瞭解 MonotaRO 的動態。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0a1d4284-1ab3-4c96-923b-30e029bae475/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0a1d4284-1ab3-4c96-923b-30e029bae475/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>TSE:3064 截至 2025 年 12 月的折現現金流</p>
<h2>關鍵要點</h2>
<ul>
<li>點擊此鏈接深入瞭解我們基於現金流的 277 家公司被低估的亞洲股票篩選器。</li>
<li>已經擁有這些公司？將您的投資組合鏈接到 Simply Wall St，並獲取有關您股票的新警告信號的提醒。</li>
<li>使用 Simply Wall St 應用程序提升您的投資能力，享受免費訪問涵蓋每個大洲的市場情報。</li>
</ul>
<h2>想探索一些替代方案嗎？</h2>
<ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>通過穩健的分紅支付者來多樣化您的投資組合，以提供可靠的收入來源，以應對潛在的市場動盪。</li>
<li>充實您的投資組合，選擇那些顯示出強勁增長潛力的公司，這些公司得到了分析師和管理層的樂觀展望支持。</li>
</ul>
<p><em>這篇文章來自 Simply Wall St，內容具有一般性。<strong>我們基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章並不構成財務建議。它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。</strong> 我們旨在為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>

三星醫療

諾瓦星雲

特寶生物

<p>亞洲股票的內在價值估計低至 26%，為投資者提供了增長機會。關鍵的被低估股票包括西安諾瓦星雲、廈門特寶生物和寧波三星醫療電氣等。儘管市場波動，這些股票顯示出顯著的盈利增長潛力。文章強調了在複雜市場環境中識別被低估股票的重要性，並提供了對其財務健康狀況和增長預測的見解</p>

<p>As global markets closely monitor economic indicators and central bank decisions, Asian stock markets are navigating a complex landscape marked by both opportunities and challenges. Amidst this environment, identifying stocks that are trading below their intrinsic value can be a strategic approach for investors looking to capitalize on potential growth opportunities in the region.</p>
<div class="lb-trans"><p>隨着全球市場密切關注經濟指標和中央銀行的決策，亞洲股市正在應對一個複雜的環境，既有機遇也有挑戰。在這種環境中，識別那些交易價格低於其內在價值的股票，對於希望在該地區抓住潛在增長機會的投資者來説，可以是一種戰略性的方法。</p>
</div><h3>Top 10 Undervalued Stocks Based On Cash Flows In Asia</h3>
<div class="lb-trans"><h3>基於現金流的亞洲十大被低估股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Current Price</strong></td>
<td><strong>Fair Value (Est)</strong></td>
<td><strong>Discount (Est)</strong></td>
</tr>
<tr>
<td>Xi'an NovaStar Tech (SZSE:301589)</td>
<td>CN¥154.22</td>
<td>CN¥302.65</td>
<td>49%</td>
</tr>
<tr>
<td>Xiamen Amoytop Biotech (SHSE:688278)</td>
<td>CN¥83.18</td>
<td>CN¥161.78</td>
<td>48.6%</td>
</tr>
<tr>
<td>Sinolong New Materials (SZSE:301565)</td>
<td>CN¥28.14</td>
<td>CN¥55.48</td>
<td>49.3%</td>
</tr>
<tr>
<td>Meitu (SEHK:1357)</td>
<td>HK$7.47</td>
<td>HK$14.60</td>
<td>48.8%</td>
</tr>
<tr>
<td>Last One MileLtd (TSE:9252)</td>
<td>¥3530.00</td>
<td>¥6867.62</td>
<td>48.6%</td>
</tr>
<tr>
<td>JUSUNG ENGINEERINGLtd (KOSDAQ:A036930)</td>
<td>₩29250.00</td>
<td>₩56972.54</td>
<td>48.7%</td>
</tr>
<tr>
<td>East Buy Holding (SEHK:1797)</td>
<td>HK$20.44</td>
<td>HK$40.26</td>
<td>49.2%</td>
</tr>
<tr>
<td>COVER (TSE:5253)</td>
<td>¥1562.00</td>
<td>¥3094.02</td>
<td>49.5%</td>
</tr>
<tr>
<td>China Ruyi Holdings (SEHK:136)</td>
<td>HK$2.41</td>
<td>HK$4.80</td>
<td>49.8%</td>
</tr>
<tr>
<td>Beijing Beimo High-tech Frictional MaterialLtd (SZSE:002985)</td>
<td>CN¥28.28</td>
<td>CN¥55.83</td>
<td>49.3%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>當前價格</strong></td>
<td><strong>公允價值（估算）</strong></td>
<td><strong>折扣（估算）</strong></td>
</tr>
<tr>
<td>西安諾瓦星科技（SZSE:301589）</td>
<td>CN¥154.22</td>
<td>CN¥302.65</td>
<td>49%</td>
</tr>
<tr>
<td>廈門特寶生物（SHSE:688278）</td>
<td>CN¥83.18</td>
<td>CN¥161.78</td>
<td>48.6%</td>
</tr>
<tr>
<td>新龍新材料（SZSE:301565）</td>
<td>CN¥28.14</td>
<td>CN¥55.48</td>
<td>49.3%</td>
</tr>
<tr>
<td>美圖（SEHK:1357）</td>
<td>HK$7.47</td>
<td>HK$14.60</td>
<td>48.8%</td>
</tr>
<tr>
<td>最後一公里有限公司（TSE:9252）</td>
<td>¥3530.00</td>
<td>¥6867.62</td>
<td>48.6%</td>
</tr>
<tr>
<td>JUSUNG ENGINEERING 有限公司（KOSDAQ:A036930）</td>
<td>₩29250.00</td>
<td>₩56972.54</td>
<td>48.7%</td>
</tr>
<tr>
<td>東買控股（SEHK:1797）</td>
<td>HK$20.44</td>
<td>HK$40.26</td>
<td>49.2%</td>
</tr>
<tr>
<td>COVER（TSE:5253）</td>
<td>¥1562.00</td>
<td>¥3094.02</td>
<td>49.5%</td>
</tr>
<tr>
<td>中國如意控股（SEHK:136）</td>
<td>HK$2.41</td>
<td>HK$4.80</td>
<td>49.8%</td>
</tr>
<tr>
<td>北京北摩高科技摩擦材料有限公司（SZSE:002985）</td>
<td>CN¥28.28</td>
<td>CN¥55.83</td>
<td>49.3%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 277 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們基於現金流的 277 只被低估亞洲股票的完整列表。</p>
</div><p>Here we highlight a subset of our preferred stocks from the screener.</p>
<div class="lb-trans"><p>在這裏，我們突出了一部分我們偏好的股票。</p>
</div><h2>Ningbo Sanxing Medical ElectricLtd (SHSE:601567)</h2>
<div class="lb-trans"><h2>寧波三星醫療電氣有限公司（SHSE:601567）</h2>
</div><p><strong>Overview:</strong> Ningbo Sanxing Medical Electric Co., Ltd. manufactures and sells power distribution products in China and internationally, with a market cap of CN¥32.52 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 寧波三星醫療電氣有限公司在中國及國際市場上製造和銷售電力配電產品，市值為 325.2 億人民幣。</p>
</div><p><strong>Operations:</strong> Ningbo Sanxing Medical Electric Co., Ltd. generates revenue by manufacturing and selling power distribution products both domestically and internationally.</p>
<div class="lb-trans"><p><strong>運營：</strong> 寧波三星醫療電氣有限公司通過製造和銷售電力配電產品在國內外產生收入。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 26%</p>
<div class="lb-trans"><p><strong>公允價值折扣估算：</strong> 26%</p>
</div><p>Ningbo Sanxing Medical Electric Ltd. is trading at CN¥23.14, significantly below its estimated fair value of CN¥31.29, indicating it may be undervalued based on cash flows. Despite recent volatility, the stock's earnings are forecast to grow 28.81% annually over the next three years, outpacing the broader Chinese market's growth rate of 27.2%. However, its dividend yield of 4.19% is not well covered by current earnings or free cash flows, presenting a potential risk for investors seeking income stability.</p>
<div class="lb-trans"><p>寧波三星醫療電氣有限公司的交易價格為 23.14 元，顯著低於其估算的公允價值 31.29 元，表明其可能被低估。儘管近期波動較大，但預計該股票的收益在未來三年將以 28.81% 的年率增長，超過中國市場整體 27.2% 的增長率。然而，其 4.19% 的股息收益率並未得到當前收益或自由現金流的良好覆蓋，這對尋求收入穩定的投資者構成潛在風險。</p>
</div><ul>
<li>Our earnings growth report unveils the potential for significant increases in Ningbo Sanxing Medical ElectricLtd's future results.</li>
<li>Get an in-depth perspective on Ningbo Sanxing Medical ElectricLtd's balance sheet by reading our health report here.</li>
</ul>
<div class="lb-trans"><ul>
<li>我們的收益增長報告揭示了寧波三星醫療電氣有限公司未來業績顯著增長的潛力。</li>
<li>通過閲讀我們的健康報告，深入瞭解寧波三星醫療電氣有限公司的資產負債表。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2ee373e6-53d5-4c83-90e5-36fd85262791/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/2ee373e6-53d5-4c83-90e5-36fd85262791/chart/dcf?theme=light"/></p>
<p>SHSE:601567 Discounted Cash Flow as at Dec 2025</p>
<div class="lb-trans"><p>SHSE:601567 截至 2025 年 12 月的折現現金流</p>
</div><h2>Nanya New Material TechnologyLtd (SHSE:688519)</h2>
<div class="lb-trans"><h2>南亞新材料科技有限公司（SHSE:688519）</h2>
</div><p><strong>Overview:</strong> Nanya New Material Technology Co., Ltd specializes in the manufacturing, design, development, and sale of composite materials with a market cap of CN¥15.91 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 南亞新材料科技有限公司專注於複合材料的製造、設計、開發和銷售，市值為 159.1 億人民幣。</p>
</div><p><strong>Operations:</strong> The company generates revenue through its core activities of manufacturing, designing, developing, and selling composite materials.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司通過其核心活動製造、設計、開發和銷售複合材料來產生收入。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 15.7%</p>
<div class="lb-trans"><p><strong>公允價值折扣估算：</strong> 15.7%</p>
</div><p>Nanya New Material Technology Ltd. is trading at CN¥69.5, below its estimated fair value of CN¥82.48, suggesting potential undervaluation based on cash flows. The company reported significant revenue growth to CN¥3.66 billion for the first nine months of 2025, with net income rising to CN¥158.1 million from the previous year’s figures. Despite a volatile share price and low forecasted return on equity, earnings are expected to grow significantly faster than the market average over the next three years.</p>
<div class="lb-trans"><p>南亞新材料科技有限公司的交易價格為 69.5 元，低於其估算的公允價值 82.48 元，表明其可能被低估。該公司報告稱，2025 年前九個月的收入顯著增長至 36.6 億人民幣，淨收入從去年同期的 158.1 百萬人民幣上升。儘管股價波動較大且預計的股本回報率較低，但預計未來三年收益將顯著快於市場平均水平。</p>
</div><ul>
<li>Insights from our recent growth report point to a promising forecast for Nanya New Material TechnologyLtd's business outlook.</li>
<li>Click to explore a detailed breakdown of our findings in Nanya New Material TechnologyLtd's balance sheet health report.</li>
</ul>
<div class="lb-trans"><ul>
<li>我們最近的增長報告提供了南亞新材料科技有限公司商業前景的良好預測。</li>
<li>點擊探索我們在南亞新材料科技有限公司資產負債表健康報告中的詳細發現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1a885788-1638-4b9b-a3c1-7d0dc71239fc/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/1a885788-1638-4b9b-a3c1-7d0dc71239fc/chart/dcf?theme=light"/></p>
<p>SHSE:688519 Discounted Cash Flow as at Dec 2025</p>
<div class="lb-trans"><p>SHSE:688519 截至 2025 年 12 月的折現現金流</p>
</div><h2>MonotaRO (TSE:3064)</h2>
<div class="lb-trans"><h2>MonotaRO（TSE:3064）</h2>
</div><p><strong>Overview:</strong> MonotaRO Co., Ltd. operates an online store for MRO products catering to factories both in Japan and internationally, with a market cap of ¥1.11 trillion.</p>
<div class="lb-trans"><p><strong>概述：</strong> MonotaRO 有限公司經營一個面向日本及國際工廠的 MRO 產品在線商店，市值為 1.11 萬億日元。</p>
</div><p><strong>Operations:</strong> The company's revenue primarily comes from its Indirect Material Sales Business for Factories, generating ¥318.01 billion.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司的收入主要來自其為工廠提供的間接材料銷售業務，收入為 3180.1 億日元。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 16.6%</p>
<div class="lb-trans"><p><strong>公允價值折扣估算：</strong> 16.6%</p>
</div><p>MonotaRO is trading at ¥2,230, below its estimated fair value of ¥2,674.47. Recent sales data shows robust growth with October 2025 sales reaching ¥29.42 billion compared to ¥25.35 billion a year earlier. Earnings are projected to grow at 13.5% annually, outpacing the JP market's average of 8.3%, while revenue growth is expected to exceed market rates as well. However, the stock has experienced high volatility recently and trades only slightly below fair value based on cash flows.</p>
<div class="lb-trans"><p>MonotaRO 的交易價格為 2230 日元，低於其估算的公允價值 2674.47 日元。最近的銷售數據顯示，2025 年 10 月的銷售額達到 294.2 億日元，而去年同期為 253.5 億日元。預計收益將以 13.5% 的年率增長，超過日本市場的平均 8.3%，同時收入增長也預計將超過市場水平。然而，該股票近期經歷了較高的波動，並且基於現金流的公允價值僅略低。</p>
</div><ul>
<li>Our expertly prepared growth report on MonotaRO implies its future financial outlook may be stronger than recent results.</li>
<li>Click here and access our complete balance sheet health report to understand the dynamics of MonotaRO.</li>
</ul>
<div class="lb-trans"><ul>
<li>我們精心準備的 MonotaRO 增長報告暗示其未來財務前景可能強於近期業績。</li>
<li>點擊這裏訪問我們的完整資產負債表健康報告，以瞭解 MonotaRO 的動態。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0a1d4284-1ab3-4c96-923b-30e029bae475/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/0a1d4284-1ab3-4c96-923b-30e029bae475/chart/dcf?theme=light"/></p>
<p>TSE:3064 Discounted Cash Flow as at Dec 2025</p>
<div class="lb-trans"><p>TSE:3064 截至 2025 年 12 月的折現現金流</p>
</div><h2>Key Takeaways</h2>
<div class="lb-trans"><h2>關鍵要點</h2>
</div><ul>
<li>Click this link to deep-dive into the 277 companies within our Undervalued Asian Stocks Based On Cash Flows screener.</li>
<li>Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.</li>
<li>Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊此鏈接深入瞭解我們基於現金流的 277 家公司被低估的亞洲股票篩選器。</li>
<li>已經擁有這些公司？將您的投資組合鏈接到 Simply Wall St，並獲取有關您股票的新警告信號的提醒。</li>
<li>使用 Simply Wall St 應用程序提升您的投資能力，享受免費訪問涵蓋每個大洲的市場情報。</li>
</ul>
</div><h2>Want To Explore Some Alternatives?</h2>
<div class="lb-trans"><h2>想探索一些替代方案嗎？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>通過穩健的分紅支付者來多樣化您的投資組合，以提供可靠的收入來源，以應對潛在的市場動盪。</li>
<li>充實您的投資組合，選擇那些顯示出強勁增長潛力的公司，這些公司得到了分析師和管理層的樂觀展望支持。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation.</strong> We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇文章來自 Simply Wall St，內容具有一般性。<strong>我們基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章並不構成財務建議。它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。</strong> 我們旨在為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div>

亞洲市場的股票估計低於其內在價值達 26%